| Name | Title | Contact Details |
|---|
Tenex Madication is a Incline Village, NV-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical compounding methods that are unmatched, especially in the areas of topical hormone replacement therapy and topical pain medications.
Novadoz Pharmaceuticals is a sales and marketing subsidiary for MSN Labs portfolio of finished dosage forms. MSN Labs is a global leader in the development and manufacturing of APIs (active pharmaceutical ingredients).
DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.